NCT03010267View on ClinicalTrials.gov

DP-R213 Phase 1 Pharmacokinetics Study

PHASE1CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

January 3, 2017

Primary Completion Date

March 8, 2017

Study Completion Date

March 29, 2017

Conditions
Healthy
Interventions
DRUG

DP-R213

Investigational product is prescribed to all of randomized subjects

DRUG

Raloxifene

Investigational product is prescribed to all of randomized subjects

DRUG

Cholecaliferol

Investigational product is prescribed to all of randomized subjects

Sponsors

Lead Sponsor

Alvogen Korea
All Listed Sponsors
lead

Alvogen Korea

INDUSTRY